01/08/2026
đĢ āĻā§āϏ āĻĒā§āϰā§āĻā§āύā§āĻā§āĻļāύ
āĻŽāĻŋāϞāĻŋāϝāĻŧāĻžāϰāĻŋ āĻāĻŋāĻāĻŦāĻžāϰāĻā§āϞā§āϏāĻŋāϏ â āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻāϰā§āĻā§āϝ
âââââââââââââââââââââââââââââ
đĩ āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻāϝāĻŧ āĻ āĻāĻĒāϏā§āĻĨāĻžāĻĒāύāĻž
ā§Šā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āĻāĻāĻāύ āĻĒā§āϰā§āώ āϰā§āĻā§ āĻā§āĻŦāϰ āĻāĻŦāĻ āϰāĻā§āϤāĻāĻžāĻļāĻŋ (hemoptysis) āύāĻŋāϝāĻŧā§ āĻāĻŽāĻžāĻĻā§āϰ āĻāĻžāĻā§ āĻāϏā§āύāĨ¤ āϰā§āĻā§āϰ āĻ
āĻŦāϏā§āĻĨāĻž āĻāĻŋāϞ āĻāĻĻā§āĻŦā§āĻāĻāύāĻ āĻāĻŦāĻ āϏāĻ āĻŋāĻ āϰā§āĻ āύāĻŋāϰā§āĻŖāϝāĻŧā§āϰ āĻāύā§āϝ āĻĻā§āϰā§āϤ āĻĒāĻĻāĻā§āώā§āĻĒ āύā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāĨ¤
đŠģ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻŦā§āĻā§āϰ āĻāĻā§āϏ-āϰ⧠(CXR) āĻĢāϞāĻžāĻĢāϞ
āĻŦā§āĻā§āϰ āĻāĻā§āϏ-āϰā§āϤ⧠āĻāĻāϝāĻŧ āĻĢā§āϏāĻĢā§āϏāĻā§āĻĄāĻŧā§ āĻāĻĄāĻŧāĻŋāϝāĻŧā§ āĻāĻŋāĻāĻŋāϝāĻŧā§ āĻ
āϏāĻāĻā§āϝ āĻā§āώā§āĻĻā§āϰ āĻā§āώā§āĻĻā§āϰ āĻāĻžāϝāĻŧāĻž (Miliary shadowing / Miliary mottling) āĻĻā§āĻāĻž āϝāĻžāϝāĻŧ â āϝāĻž Miliary Tuberculosis-āĻāϰ āϏā§āϏā§āĻĒāώā§āĻ āĻāĻŋāϤā§āϰāĨ¤ āĻāĻ āϧāϰāύā§āϰ āĻāĻĄāĻŧāĻŋāϝāĻŧā§ āĻĒāĻĄāĻŧāĻž TB āϏāĻāĻā§āϰāĻŽāĻŖ āĻ
āϤā§āϝāύā§āϤ āĻā§āϰā§āϤāϰ āĻāĻŦāĻ āĻĻā§āϰā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻž āĻāϰāϞ⧠āĻĒā§āϰāĻžāĻŖāĻāĻžāϤ⧠āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
đŦ āϰā§āĻ āύāĻŋāϰā§āĻŖāϝāĻŧ
āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒāϰā§āĻā§āώāĻž, āϰā§āĻĄāĻŋāĻāϞāĻāĻŋāĻā§āϝāĻžāϞ āĻĢāϞāĻžāĻĢāϞ āĻāĻŦāĻ āĻ
āύā§āϝāĻžāύā§āϝ āϤāĻĻāύā§āϤā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āϰā§āĻā§āĻā§ Miliary Tuberculosis āĻšāĻŋāϏā§āĻŦā§ āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž āĻšāϝāĻŧ āĻāĻŦāĻ WHO-āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ Anti-Tubercular Treatment (ATT) āĻļā§āϰ⧠āĻāϰāĻž āĻšāϝāĻŧāĨ¤
đ āĻāĻŋāĻāĻŋā§āϏāĻž
âļ Intensive phase (⧍ āĻŽāĻžāϏ): Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E)
âļ Continuation phase (ā§Ē āĻŽāĻžāϏ): Isoniazid (H) + Rifampicin (R)
âļ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ follow-up, liver function āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāĻŦāĻ āϰā§āĻā§āϰ adherence āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšāϝāĻŧ
â
āĻāĻŋāĻāĻŋā§āϏāĻž-āĻĒāϰāĻŦāϰā§āϤ⧠āĻŦā§āĻā§āϰ āĻāĻā§āϏ-āϰ⧠â āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āĻāύā§āύāϤāĻŋ!
ATT āϏāĻŽā§āĻĒāύā§āύ āĻšāĻāϝāĻŧāĻžāϰ āĻĒāϰ follow-up āĻŦā§āĻā§āϰ āĻāĻā§āϏ-āϰā§āϤ⧠āĻĻā§āĻāĻž āϝāĻžāϝāĻŧ â āĻāĻā§āϰ āϏā§āĻ āĻāĻĄāĻŧāĻŋāϝāĻŧā§ āĻĒāĻĄāĻŧāĻž miliary shadowing āϏāĻŽā§āĻĒā§āϰā§āĻŖāϰā§āĻĒā§ āĻ
āĻĻā§āĻļā§āϝ āĻšāϝāĻŧā§ āĻā§āĻā§! āĻĢā§āϏāĻĢā§āϏ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āĻāĻŦāĻ āϰā§āĻā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϏā§āϏā§āĻĨāĨ¤
đ āĻāĻ āĻā§āϏ āĻĨā§āĻā§ āĻļāĻŋāĻā§āώāĻŖā§āϝāĻŧ āĻŦāĻŋāώāϝāĻŧ
1. āĻā§āĻŦāϰ āĻ hemoptysis āϏāĻš āϰā§āĻā§āϤ⧠āϏāĻŦāϏāĻŽāϝāĻŧ Miliary TB āĻŽāĻžāĻĨāĻžāϝāĻŧ āϰāĻžāĻāϤ⧠āĻšāĻŦā§
2. Miliary TB-āϤ⧠CXR-āĻ bilateral diffuse millet seed-like opacities āĻĻā§āĻāĻž āϝāĻžāϝāĻŧ
3. āϏāĻŽāϝāĻŧāĻŽāϤ⧠āϏāĻ āĻŋāĻ ATT āĻļā§āϰ⧠āĻāϰāϞ⧠āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϰā§āĻĄāĻŋāĻāϞāĻāĻŋāĻā§āϝāĻžāϞ clearance āϏāĻŽā§āĻāĻŦ
4. ATT-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ follow-up āĻ drug compliance āĻ
āϤā§āϝāύā§āϤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ
5. Miliary TB āĻāĻāĻāĻŋ medical emergency â āĻĻā§āϰāĻŋ āύāĻž āĻāϰ⧠āĻĻā§āϰā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž āĻļā§āϰ⧠āĻāϰā§āύ
âââââââââââââââââââââââââââââ
āϏāĻā§āϤāύ āĻĨāĻžāĻā§āύāĨ¤ āϏā§āϏā§āĻĨ āĻĨāĻžāĻā§āύāĨ¤ āϏāĻ āĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āϝāĻā§āώā§āĻŽāĻž āϏāĻŽā§āĻĒā§āϰā§āĻŖ āύāĻŋāϰāĻžāĻŽāϝāĻŧāϝā§āĻā§āϝāĨ¤ đ
#āϝāĻā§āώā§āĻŽāĻž